|
|
Article: Xencor and Genentech to Collaborate to Develop Next-Generation Antibody Therapeutics.
- Article from:
- Business Wire
- Article date:
- December 1, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MONROVIA, Calif. -- Genentech Licenses Xencor's XmAb(TM) Technology for CD20 and Her2, Key Cancer and Autoimmune Targets
Xencor today announced a license and collaboration agreement with Genentech, Inc. (NYSE:DNA) to create next-generation therapeutic antibodies for cancer and autoimmune diseases. Under the terms of the agreement, Xencor will grant to Genentech an exclusive, worldwide license to use Xencor's XmAb technology to develop and commercialize products directed against two clinically and commercially validated antibody targets, CD20 and Her2, and a third undisclosed antigen. Rituxan(R) (rituximab) targets CD20 and is marketed by Genentech and Biogen-Idec ...